Overexpression of TIPE2, a Negative Regulator of Innate and Adaptive Immunity, Attenuates Cognitive Deficits in APP/PS1 Mice

J Neuroimmune Pharmacol. 2019 Sep;14(3):519-529. doi: 10.1007/s11481-019-09861-2. Epub 2019 Jul 8.

Abstract

Neuroinflammation plays an early and prominent role in the pathology of Alzheimer's disease (AD). Tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) has been identified as a negative regulator of innate and adaptive immunity. However, whether TIPE2 affects cognitive functions in AD-like mouse models remains unknown. In this study, we compared the gene and protein expressions of TIPE2 between the APP/PS1 mice and the age-matched wild type (WT) mice at different stages of development using western blot and RT-qPCR. The hippocampal expression of the TIPE2 mRNA and protein in APP/PS1 mice was higher than that of the WT mice starting from 6 months to 10 months. However, the difference of the TIPE2 expression between the APP/PS1 mice and the WT mice declined in a time-dependent manner. The spatial learning and memory deficit from the 8-month-old APP/PS1 mice was observed in the Y-maze test and fear conditioning task. Interestingly, overexpression of TIPE2 by intra-hippocampal injection of AAV-TIPE2 into APP/PS1 mice resulted in an improvement of learning and memory and reduced expression of inflammatory cytokines, such as TNF-α, IL-6 and IL-1β, and increased expression of anti-inflammatory cytokines, such as IL-10 and Arg-1. Taken together, our findings show that the TIPE2 expression level was negatively correlated with the pathogenesis of Alzheimer's disease, and overexpression of TIPE2 attenuates cognitive deficits in APP/PS1 mice, suggesting TIPE2 is a potential target for pharmacological intervention and improvement of cognitive deficits. Graphical Abstract .

Keywords: APP/PS1 transgenic mice; Alzheimer’s disease; Hippocampus; TIPE2; Y-maze.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptive Immunity
  • Alzheimer Disease / immunology*
  • Alzheimer Disease / psychology
  • Alzheimer Disease / therapy
  • Amyloid beta-Protein Precursor / genetics
  • Animals
  • Cognition Disorders / etiology
  • Cognition Disorders / immunology
  • Cognition Disorders / prevention & control
  • Cytokines / biosynthesis
  • Cytokines / genetics
  • Dependovirus / genetics
  • Disease Models, Animal
  • Fear
  • Gene Expression Regulation, Developmental
  • Genetic Therapy
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / therapeutic use
  • Hippocampus
  • Immunity, Innate
  • Injections
  • Intracellular Signaling Peptides and Proteins / biosynthesis
  • Intracellular Signaling Peptides and Proteins / genetics
  • Intracellular Signaling Peptides and Proteins / physiology*
  • Maze Learning
  • Memory Disorders / etiology
  • Memory Disorders / immunology
  • Memory Disorders / prevention & control*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Presenilin-1 / genetics
  • Recombinant Proteins / metabolism
  • Up-Regulation

Substances

  • Amyloid beta-Protein Precursor
  • Cytokines
  • Intracellular Signaling Peptides and Proteins
  • PSEN1 protein, human
  • Presenilin-1
  • Recombinant Proteins
  • TIPE2 protein, mouse